Public Market Listing
Live quotes, historical charts, and market capitalization for ImmuneOnco Biopharmaceuticals are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | PD-L1 / VEGFMultispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1/2 | Activin receptor type IIA (ActRIIA)Biologic (subtype unspecified) | Indication not yet linked |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $5.3M | $23M | — | — | report ↗ |
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $45M | — | $44M | report ↗ |
ImmuneOnco Biopharmaceuticals reported R&D spend of $44.93M and a quarterly net burn of $43.97M for fiscal year 2024.
Figures only: this period's report disclosed no narrative text